Retrospective Cohort Study
Copyright ©The Author(s) 2023.
World J Gastrointest Surg. Jan 27, 2023; 15(1): 32-48
Published online Jan 27, 2023. doi: 10.4240/wjgs.v15.i1.32
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1  Flowchart of study population enrollment.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Comparison of overall survival and progression-free survival before and after propensity score matching in stage II gastric cancer patients. A: Comparison of overall survival between the two groups based on chemotherapy cycles before propensity score matching (PSM); B: Comparison of progression-free survival between the two groups based on chemotherapy cycles before PSM; C and D: Comparison of overall survival (C) and progression-free survival (D) between the two groups based on chemotherapy cycles after PSM.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Subgroup analysis of overall survival and progression-free survival based on chemotherapy cycles in stage II gastric cancer patients. A: Overall survival; B: Progression-free survival.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Comparison of overall survival and progression-free survival before and after propensity score matching in stage III gastric cancer patients. A: Comparison of overall survival between the two groups based on chemotherapy cycles before propensity score matching (PSM); B: Comparison of progression-free survival between the two groups based on chemotherapy cycles before PSM; C and D: Comparison of overall survival (C) and progression-free survival (D) between the two groups based on chemotherapy cycles after PSM.
Figure 5
Open in New Tab Full Size Figure Download Figure
Figure 5 Subgroup analysis of overall survival and progression-free survival for chemotherapy cycles in stage III gastric cancer patients. A: Subgroup analyses of overall survival based on chemotherapy cycles; B: Subgroup analyses of progression-free survival based on chemotherapy cycles.